UP!
 |
|
|
Type
|
Public company |
|---|---|
| Traded as | NASDAQ: ICPT Russell 1000 Component |
| Industry | Biotechnology |
| Founded | 2002 |
| Headquarters | New York City, New York, United States |
|
Key people
|
Mark Pruzanski (President and CEO) Jonathan Silverstein (Chairman of the Board of Directors) |
| Website | www |
Coordinates: 40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W / 40.678631; -78.243038
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
The company's lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis. It is in phase III studies for non-alcoholic steatohepatitis (NASH) and phase II studies for primary sclerosing cholangitis.
Other products in the development pipeline include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.
Intercept trades on the NASDAQ exchange under the ticker symbol ICPT. The initial public offering of the stock on October 16, 2012 was at $15. A follow-on public offering at $33 took place on June 24, 2013.
On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by NIDDK. The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.
In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum alkaline phosphatase, a biomarker for the disease. These results were presented at an international liver meeting in April 2014.
As of 31 December 2014, the company had 136 employees.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-03 | -0.25 | -0.25 |
| Q1 2022 | 2022-05-06 | -0.58 | -0.58 |
| Q4 2021 | 2022-03-02 | -1.23 | -1.23 |
| Q3 2021 | 2021-11-03 | -0.11 | -0.11 |
| Q2 2021 | 2021-07-29 | -0.33 | -0.33 |
| Q1 2021 | 2021-05-06 | -1.22 | -1.22 |
| Q4 2020 | 2021-02-25 | -1.58 | -1.58 |
| Q3 2020 | 2020-11-09 | -2.01 | -2.01 |
| Q2 2020 | 2020-08-10 | -1.92 | -1.92 |
| 2016-07-09 | Reiterated Rating | Wedbush | Buy | |
| 2016-07-06 | Initiated Coverage | Cantor Fitzgerald | Sell | $58.00 |
| 2016-06-24 | Reiterated Rating | Wedbush | Outperform | $239.00 |
| 2016-06-15 | Reiterated Rating | Robert W. Baird | Outperform | $332.00 |
| 2016-06-09 | Reiterated Rating | Robert W. Baird | Outperform | $332.00 |
| 2016-06-01 | Reiterated Rating | Robert W. Baird | Outperform | $332.00 |
| 2016-06-01 | Reiterated Rating | Needham & Company LLC | Buy | $350.00 |
| 2016-06-01 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-06-01 | Reiterated Rating | Barclays | Buy | $200.00 to $205.00 |
| 2016-06-01 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | |
| 2016-06-01 | Reiterated Rating | Barclays PLC | Buy | $200.00 to $205.00 |
| 2016-05-31 | Reiterated Rating | Wedbush | Outperform | $423.00 to $239.00 |
| 2016-05-31 | Reiterated Rating | Credit Suisse | Buy | $200.00 |
| 2016-05-31 | Reiterated Rating | Morgan Stanley | Underweight | $80.00 |
| 2016-05-31 | Reiterated Rating | JMP Securities | Market Outperform | $200.00 |
| 2016-05-31 | Boost Price Target | Cowen and Company | Outperform | $212.00 to $215.00 |
| 2016-05-31 | Boost Price Target | Goldman Sachs | Neutral | $114.00 to $128.00 |
| 2016-05-31 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-05-31 | Reiterated Rating | FBR & Co. | Hold | $192.00 to $200.00 |
| 2016-05-31 | Reiterated Rating | Leerink Swann | Hold | $144.00 to $140.00 |
| 2016-05-31 | Reiterated Rating | BMO Capital Markets | Buy | $221.00 to $219.00 |
| 2016-05-31 | Reiterated Rating | Wells Fargo & Co. | Buy | |
| 2016-05-31 | Reiterated Rating | FBR & Co | Hold | $192.00 to $200.00 |
| 2016-05-31 | Reiterated Rating | Credit Suisse Group AG | Buy | $200.00 |
| 2016-05-31 | Boost Price Target | Goldman Sachs Group Inc. | Neutral | $114.00 to $128.00 |
| 2016-05-20 | Reiterated Rating | Needham & Company LLC | Buy | $350.00 |
| 2016-05-10 | Reiterated Rating | Credit Suisse | Buy | $200.00 |
| 2016-05-10 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-05-09 | Upgrade | FBR & Co. | Marketperform to Outperform | |
| 2016-05-08 | Reiterated Rating | Morgan Stanley | Sell | |
| 2016-05-08 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-05-06 | Reiterated Rating | Wedbush | Outperform | |
| 2016-05-06 | Reiterated Rating | Cowen and Company | Buy | $212.00 |
| 2016-05-03 | Reiterated Rating | BMO Capital Markets | Buy | $239.00 |
| 2016-05-03 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-04-17 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-12 | Reiterated Rating | BMO Capital Markets | Outperform | $239.00 |
| 2016-04-09 | Reiterated Rating | Cowen and Company | Buy | $212.00 |
| 2016-04-09 | Reiterated Rating | Morgan Stanley | Equal to Sell | |
| 2016-04-09 | Reiterated Rating | Bank of America | Sell | $144.00 |
| 2016-04-09 | Reiterated Rating | Needham & Company LLC | Buy | $350.00 |
| 2016-04-09 | Reiterated Rating | Oppenheimer | Buy | $309.00 |
| 2016-04-09 | Reiterated Rating | Bank of America Corp. | Sell | $144.00 |
| 2016-04-08 | Downgrade | Morgan Stanley | Equal Weight to Underperform | $100.00 to $80.00 |
| 2016-04-07 | Reiterated Rating | Wedbush | Outperform | $423.00 |
| 2016-04-07 | Reiterated Rating | Credit Suisse | Buy | $200.00 |
| 2016-04-06 | Initiated Coverage | BMO Capital Markets | Outperform | |
| 2016-04-06 | Reiterated Rating | Leerink Swann | Hold | $144.00 |
| 2016-04-05 | Reiterated Rating | FBR & Co. | Hold | $192.00 |
| 2016-04-05 | Reiterated Rating | Robert W. Baird | Buy | $32.00 |
| 2016-04-05 | Upgrade | Wells Fargo | Market Perform to Outperform | |
| 2016-04-01 | Reiterated Rating | Wells Fargo | Hold | $171.00 |
| 2016-04-01 | Reiterated Rating | Morgan Stanley | Equal Weight | $100.00 |
| 2016-03-30 | Reiterated Rating | Wedbush | Outperform | |
| 2016-03-30 | Reiterated Rating | JMP Securities | Buy | $200.00 |
| 2016-03-30 | Initiated Coverage | Goldman Sachs | Buy to Neutral | $114.00 |
| 2016-03-30 | Initiated Coverage | Credit Suisse | Outperform | $200.00 |
| 2016-03-28 | Reiterated Rating | Cowen and Company | Buy | $212.00 |
| 2016-03-23 | Reiterated Rating | Leerink Swann | Market Perform | |
| 2016-03-08 | Reiterated Rating | Cowen and Company | Outperform | $212.00 |
| 2016-02-26 | Lower Price Target | Oppenheimer | Outperform | $309.00 |
| 2016-02-26 | Lower Price Target | Cowen and Company | Outperform | $212.00 |
| 2016-02-24 | Lower Price Target | Barclays | Overweight | $300.00 to $200.00 |
| 2016-02-23 | Reiterated Rating | Wedbush | Outperform | $493.00 to $423.00 |
| 2016-01-29 | Upgrade | Morgan Stanley | Underweight to Equal Weight | $100.00 |
| 2016-01-28 | Reiterated Rating | S&P Equity Research | Average | $100.60 to $111.91 |
| 2016-01-27 | Reiterated Rating | Needham & Company LLC | Buy | $500.00 |
| 2016-01-04 | Reiterated Rating | Wedbush | Outperform | $493.00 |
| 2015-12-27 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2015-12-21 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2015-12-21 | Reiterated Rating | Leerink Swann | Hold | $214.00 |
| 2015-12-18 | Reiterated Rating | Robert W. Baird | Buy | $346.00 |
| 2015-12-18 | Lower Price Target | JMP Securities | Market Outperform | $348.00 |
| 2015-12-17 | Reiterated Rating | FBR & Co. | Market Perform | $192.00 |
| 2015-12-03 | Reiterated Rating | Needham & Company LLC | Buy | $500.00 |
| 2015-12-03 | Initiated Coverage | Wells Fargo | Market Perform | |
| 2015-12-02 | Reiterated Rating | Leerink Swann | Hold | $220.00 to $214.00 |
| 2015-12-02 | Reiterated Rating | Wedbush | Outperform | $493.00 |
| 2015-11-19 | Reiterated Rating | Wedbush | Buy | |
| 2015-11-18 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-11-18 | Initiated Coverage | Needham & Company LLC | Buy | |
| 2015-11-13 | Reiterated Rating | Wedbush | Outperform | |
| 2015-11-12 | Reiterated Rating | Cowen and Company | Outperform | $412.00 |
| 2015-11-11 | Lower Price Target | FBR & Co. | Market Perform | $273.00 to $192.00 |
| 2015-11-10 | Lower Price Target | Leerink Swann | Market Perform | $265.00 to $220.00 |
| 2015-11-09 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2015-11-09 | Reiterated Rating | Robert W. Baird | Buy | $346.00 |
| 2015-10-30 | Reiterated Rating | FBR & Co. | Marketperform | |
| 2015-10-29 | Reiterated Rating | Morgan Stanley | Sell | $165.00 to $110.00 |
| 2015-10-28 | Reiterated Rating | Robert W. Baird | Buy | $346.00 |
| 2015-10-28 | Reiterated Rating | Needham & Company LLC | Buy | $500.00 |
| 2015-10-28 | Downgrade | Bank of America | Neutral to Underperform | $268.00 to $157.00 |
| 2015-09-29 | Reiterated Rating | FBR & Co. | Positive | $273.00 |
| 2015-08-31 | Reiterated Rating | Wedbush | Buy | $493.00 |
| 2015-08-13 | Initiated Coverage | Morgan Stanley | Underweight | $165.00 |
| 2015-08-10 | Reiterated Rating | Wedbush | Outperform | |
| 2015-08-07 | Initiated Coverage | Needham & Company LLC | Buy | $500.00 |
| 2015-08-07 | Reiterated Rating | Janney Montgomery Scott | Buy | |
| 2015-08-06 | Reiterated Rating | Cowen and Company | Buy | $420.00 to $412.00 |
| 2015-08-04 | Reiterated Rating | Wedbush | Buy | |
| 2015-07-24 | Reiterated Rating | RBC Capital | Outperform | $490.00 |
| 2015-07-24 | Reiterated Rating | Royal Bank Of Canada | Outperform | $490.00 |
| 2015-07-03 | Reiterated Rating | Oppenheimer | Outperform | $375.00 |
| 2015-07-01 | Reiterated Rating | MLV & Co. | Hold | |
| 2015-06-30 | Reiterated Rating | Wedbush | Buy | $493.00 |
| 2015-06-30 | Reiterated Rating | Robert W. Baird | Buy | $344.00 |
| 2015-06-06 | Reiterated Rating | Wedbush | Outperform | |
| 2015-05-21 | Initiated Coverage | Barclays | Overweight | $425.00 |
| 2015-05-20 | Reiterated Rating | Wedbush | Outperform | |
| 2015-05-19 | Set Price Target | BMO Capital Markets | Buy | $515.00 |
| 2015-05-19 | Downgrade | Bank of America | Buy to Neutral | $315.00 |
| 2015-05-12 | Reiterated Rating | Wedbush | Outperform | $493.00 |
| 2015-05-12 | Set Price Target | RBC Capital | Positive to Buy | $490.00 |
| 2015-05-11 | Reiterated Rating | Needham & Company LLC | Buy | $500.00 |
| 2015-05-11 | Boost Price Target | Janney Montgomery Scott | Buy | $350.00 to $363.00 |
| 2015-04-23 | Reiterated Rating | Wedbush | Buy | |
| 2015-04-01 | Set Price Target | Wedbush | Buy | $493.00 |
| 2015-03-27 | Set Price Target | MLV & Co. | Hold | $273.00 |
| 2015-03-27 | Boost Price Target | Deutsche Bank | Buy | $300.00 to $400.00 |
| 2015-03-27 | Boost Price Target | Deutsche Bank AG | Buy | $300.00 to $400.00 |
| 2015-03-24 | Reiterated Rating | Wedbush | Buy | $493.00 |
| 2015-03-23 | Set Price Target | Needham & Company LLC | Buy | $500.00 |
| 2015-03-23 | Boost Price Target | Leerink Swann | Market Perform | $205.00 to $265.00 |
| 2015-03-23 | Set Price Target | Janney Montgomery Scott | Buy to Buy | $300.00 to $350.00 |
| 2015-03-20 | Set Price Target | Nomura | Buy | $440.00 |
| 2015-03-20 | Set Price Target | Nomura Holdings Inc. | Buy | $440.00 |
| 2015-03-18 | Boost Price Target | Robert W. Baird | Buy | $258.00 to $344.00 |
| 2015-03-17 | Initiated Coverage | MLV & Co. | Hold | $273.00 |
| 2015-03-02 | Reiterated Rating | Janney Montgomery Scott | Buy | |
| 2015-01-28 | Lower Price Target | Oppenheimer | Outperform | $499.00 to $375.00 |
| 2015-01-15 | Set Price Target | Cowen and Company | Buy | $420.00 |
| 2015-01-06 | Set Price Target | Cowen and Company | Buy | $420.00 |
| 2015-01-05 | Set Price Target | Robert W. Baird | Buy | $258.00 |
| 2014-12-18 | Initiated Coverage | Janney Montgomery Scott | Buy | |
| 2014-12-18 | Initiated Coverage | Sterne Agee CRT | Buy | |
| 2014-12-15 | Reiterated Rating | Bank of America | Buy | $188.00 |
| 2014-12-04 | Initiated Coverage | Robert W. Baird | Outperform | $258.00 |
| 2014-12-03 | Lower Price Target | FBR & Co. | Underperform | $125.00 to $99.00 |
| 2014-11-11 | Reiterated Rating | Nomura | Buy | |
| 2014-11-10 | Lower Price Target | FBR & Co. | Underperform | $172.00 to $125.00 |
| 2014-11-07 | Downgrade | Leerink Swann | Outperform to Market Perform | $445.00 to $191.00 |
| 2014-11-04 | Reiterated Rating | Summer Street | Positive | |
| 2014-10-23 | Reiterated Rating | Nomura | Buy | |
| 2014-09-05 | Initiated Coverage | Cowen and Company | Outperform | $420.00 |
| 2014-08-15 | Initiated Coverage | FBR & Co. | Underperform | $172.00 |
| 2014-08-12 | Reiterated | RBC Capital Mkts | Outperform | $425 to $500 |
| 2014-08-12 | Upgrade | Leerink Swann | Market Perform to Outperform | $270.00 to $445.00 |
| 2014-07-29 | Upgrade | Nomura | Neutral to Buy | $323.00 |
| 2014-07-14 | Initiated Coverage | Deutsche Bank | Buy | $395.00 |
| 2014-07-02 | Initiated Coverage | Goldman Sachs | Neutral | $265.00 |
| 2014-06-30 | Initiated Coverage | RBC Capital | Outperform | $425.00 |
| 2014-06-27 | Reiterated Rating | Summer Street | Buy | |
| 2014-06-26 | Initiated Coverage | Leerink Swann | Market Perform | $270.00 |
| 2014-06-26 | Initiated Coverage | Nomura | Neutral | $294.00 |
| 2014-04-14 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2014-01-22 | Boost Price Target | Wedbush | Fair Value | $72.00 to $449.00 |
| 2014-01-13 | Reiterated Rating | BMO Capital Markets | Outperform | |
| 2014-01-10 | Reiterated | Needham | Buy | $55 to $320 |
| 2014-01-10 | Boost Price Target | Janney Montgomery Scott | $300.00 | |
| 2014-01-10 | Boost Price Target | Needham & Company LLC | Buy | $55.00 to $320.00 |
| 2014-01-10 | Boost Price Target | Oppenheimer | Outperform | $94.00 to $360.00 |
| 2014-01-10 | Reiterated Rating | Citigroup Inc. | Buy | $60.00 to $400.00 |
| 2014-01-09 | Boost Price Target | BMO Capital Markets | $270.00 to $375.00 | |
| 2013-10-01 | Boost Price Target | Oppenheimer | Outperform | $64.00 to $94.00 |
| 2013-09-20 | Boost Price Target | BMO Capital Markets | Outperform | $62.00 to $107.00 |
| 2013-01-16 | Reiterated | Wedbush | Outperform | $25 to $46 |
| 2016-07-09 | Reiterated Rating | Wedbush | Buy | |
| 2016-07-06 | Initiated Coverage | Cantor Fitzgerald | Sell | $58.00 |
| 2016-06-24 | Reiterated Rating | Wedbush | Outperform | $239.00 |
| 2016-06-15 | Reiterated Rating | Robert W. Baird | Outperform | $332.00 |
| 2016-06-09 | Reiterated Rating | Robert W. Baird | Outperform | $332.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ICPT 133 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| STATE STREET CORP | 3.05M |
| BlackRock Inc. | 2.94M |
| Vanguard Group, Inc | 2.71M |
| Point72 Asset Management, L.P. | 1.56M |
| FMR LLC | 0.93M |
| CITADEL ADVISORS LLC | 0.92M |
| MORGAN STANLEY | 0.90M |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.80M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.78M |
| RENAISSANCE TECHNOLOGIES LLC | 0.74M |
| BANK OF AMERICA CORP /DE/ | 0.67M |
| MACQUARIE GROUP LTD | 0.66M |
| TWO SIGMA ADVISERS, LLC | 0.63M |
| BlackRock Fund Advisors | 0.56M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.45M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Genextra S.p.A. | 32.26% (6845578) | ICPT / |
| Micheli Francesco | 32.26% (6845578) | ICPT / |
| ORBIMED ADVISORS LLC | 5.28% (1120609) | AGLE / AMBI / ANTH / ATHX / BOLD / BONE / CRVS / CTIC / ICPT / KALA / LOXO / MRTX / OTIC / RLYP / ROKA / SIEN / SUPN / SYBX / XLRN / |
| Pruzanski Mark President and CEO | 2.72% (576564) | ICPT / |
| AKKARAJU SRINIVAS | 1.10% (234375) | ICPT / SGEN / VSAR / ZSPH / |
| Shapiro David CMO & EVP - Development | 0.22% (47113) | ICPT / |
| Duncan Barbara Gayle Chief Financial Officer | 0.15% (30808) | ICPT / MDGN / THRX / |
| Bright Lisa See Remarks | 0.14% (30385) | ICPT / |
| Durso Jerome Benedict Chief Operating Officer | 0.13% (28600) | ICPT / |
| Kapadia Sandip Chief Financial Officer | 0.13% (27115) | ICPT / |
| Sullivan Ryan T General Counsel | 0.11% (23200) | ANAC / ICPT / |
| Weyer Christian EVP Research and Development | 0.09% (18600) | FATE / ICPT / |
| Kim Richard J SVP, Commercial US | 0.08% (17005) | ICPT / |
| McMinn Rachel Chief Strategy Officer | 0.08% (16875) | ICPT / |
| Adorini Luciano Chief Scientific Officer | 0.06% (11959) | ICPT / |
| BRADBURY DANIEL | 0.05% (11642) | BMR / CORT / GERN / ICPT / ILMN / |
| Fundaro Paolo | 0.05% (11498) | ICPT / |
| Ford David A Chief Human Resources Officer | 0.05% (10300) | ICPT / |
| Gottesdiener Keith Michael | 0.02% (5001) | ICPT / |
| Luca Benatti | 0.02% (4569) | ICPT / |
| SANTINI GINO | 0.02% (3927) | AMAG / HZNP / ICPT / VTAE / |
| SBLENDORIO GLENN | 0.02% (3729) | FOLD / ICPT / MDCO / OPHT / |
| WELCH DANIEL G | 0.01% (3108) | HPTX / ICPT / ITMN / SGEN / |
| VEITINGER KLAUS R DR | 0.01% (2816) | ICPT / RLYP / |
| Regan Daniel Paul Chief Commercial Officer | 0.01% (1264) | ICPT / KERX / |
| SILVERSTEIN JONATHAN | 0.01% (1259) | ICPT / RLYP / ROKA / |
UM